CN102203098A - 作为细胞增殖抑制剂的嘧啶并[5,4-d]嘧啶 - Google Patents

作为细胞增殖抑制剂的嘧啶并[5,4-d]嘧啶 Download PDF

Info

Publication number
CN102203098A
CN102203098A CN2009801439757A CN200980143975A CN102203098A CN 102203098 A CN102203098 A CN 102203098A CN 2009801439757 A CN2009801439757 A CN 2009801439757A CN 200980143975 A CN200980143975 A CN 200980143975A CN 102203098 A CN102203098 A CN 102203098A
Authority
CN
China
Prior art keywords
alkyl
compound
hydrogen
optionally substituted
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801439757A
Other languages
English (en)
Chinese (zh)
Inventor
安德烈亚斯.曼托里迪斯
乔格.达曼
彼得.艾特迈耶
克里斯琴.克莱因
斯蒂芬.斯图勒
艾琳.威泽尼格
斯蒂芬.K.扎恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40297852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102203098(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN102203098A publication Critical patent/CN102203098A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2009801439757A 2008-09-08 2009-09-08 作为细胞增殖抑制剂的嘧啶并[5,4-d]嘧啶 Pending CN102203098A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08163897 2008-09-08
EP08163897.5 2008-09-08
PCT/EP2009/061656 WO2010026262A1 (en) 2008-09-08 2009-09-08 Pyrido [5, 4-d] pyrimidines as cell proliferation inhibitors

Publications (1)

Publication Number Publication Date
CN102203098A true CN102203098A (zh) 2011-09-28

Family

ID=40297852

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801439757A Pending CN102203098A (zh) 2008-09-08 2009-09-08 作为细胞增殖抑制剂的嘧啶并[5,4-d]嘧啶

Country Status (16)

Country Link
US (1) US8653087B2 (cg-RX-API-DMAC7.html)
EP (1) EP2350083B1 (cg-RX-API-DMAC7.html)
JP (1) JP5576379B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110063528A (cg-RX-API-DMAC7.html)
CN (1) CN102203098A (cg-RX-API-DMAC7.html)
AR (1) AR073501A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009289196A1 (cg-RX-API-DMAC7.html)
CA (1) CA2736306A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011000489A1 (cg-RX-API-DMAC7.html)
IL (1) IL211136A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011002431A (cg-RX-API-DMAC7.html)
NZ (1) NZ591493A (cg-RX-API-DMAC7.html)
RU (1) RU2011113402A (cg-RX-API-DMAC7.html)
TW (1) TW201014860A (cg-RX-API-DMAC7.html)
WO (1) WO2010026262A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201101090B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117177973A (zh) * 2021-04-19 2023-12-05 蒙特利尔大学 吡啶并[3,2-d]嘧啶化合物及其用于治疗增殖性疾病的用途

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001943A1 (es) * 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
EP2350052B1 (en) 2008-09-29 2014-08-13 Boehringer Ingelheim International GmbH Antiproliferative compounds
EP2398797B1 (en) * 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
CN105853415A (zh) 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
BRPI1014322A2 (pt) 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー N−置換ヘテロシクリルカルボキサミド類
IN2014DN07954A (cg-RX-API-DMAC7.html) 2012-03-13 2015-05-01 Basf Se
CA2923101A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
EP3609882B1 (en) 2017-03-17 2022-07-13 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of pcsk9
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
AU2022260863B2 (en) * 2021-04-19 2025-06-19 Universite De Montreal Pyrimido[5,4,d]pyrimidine compounds, compositions comprising them and uses thereof
JP2025535134A (ja) * 2022-10-13 2025-10-22 ユニヴェルシテ ド モントリオール チアゾロ[5,4-d]ピリミジン化合物、該化合物を含む組成物、及びそれらの使用方法
AU2023410324A1 (en) 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
CN121568696A (zh) 2023-07-28 2026-02-24 勃林格殷格翰国际有限公司 制备her2抑制剂的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1139383A (zh) * 1994-01-25 1997-01-01 沃尼尔朗伯公司 能够抑制表皮生长因子受体族酪氨酸激酶的双环化合物
CN1212696A (zh) * 1996-03-06 1999-03-31 卡尔·托马博士公司 嘧啶并[5,4-d]嘧啶,含这种化合物的药物,它们的用途和其制备方法
CA2650611A1 (en) * 2006-05-15 2007-11-29 Irm Llc Compositions and methods for fgf receptor kinases inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
CA2223081C (en) * 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AR007855A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
DE19911510A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
ATE329909T1 (de) 2002-11-27 2006-07-15 Boehringer Ingelheim Pharma 1,2,3-triazolamid-derivate als cytokininhibitoren
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
US7511042B2 (en) 2003-12-03 2009-03-31 Boehringer Ingelheim Pharmaceuticals, Inc. Triazole compounds
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
EP1725544B1 (en) 2004-03-09 2009-05-27 Boehringer Ingelheim Pharmaceuticals Inc. 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
US7485657B2 (en) 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
JP2007076376A (ja) 2005-09-09 2007-03-29 Yanmar Co Ltd トラクタ
WO2007056016A2 (en) 2005-11-02 2007-05-18 Kemia, Inc. Bisamide cytokine inhibitors
WO2007075896A2 (en) 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
JP2009536618A (ja) 2006-04-18 2009-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 4−及び5−イミダゾリル環を含むサイトカイン阻害化合物の製造方法及びその中間体
PE20080401A1 (es) 2006-07-07 2008-06-23 Boehringer Ingelheim Int DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
WO2008089034A2 (en) 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
US20100144764A1 (en) 2007-04-13 2010-06-10 Schering Corporation Pyrimidinedione derivatives and methods of use thereof
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CA2692379A1 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン,インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
EP2350052B1 (en) 2008-09-29 2014-08-13 Boehringer Ingelheim International GmbH Antiproliferative compounds
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
EP2398797B1 (en) 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1139383A (zh) * 1994-01-25 1997-01-01 沃尼尔朗伯公司 能够抑制表皮生长因子受体族酪氨酸激酶的双环化合物
CN1212696A (zh) * 1996-03-06 1999-03-31 卡尔·托马博士公司 嘧啶并[5,4-d]嘧啶,含这种化合物的药物,它们的用途和其制备方法
CA2650611A1 (en) * 2006-05-15 2007-11-29 Irm Llc Compositions and methods for fgf receptor kinases inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117177973A (zh) * 2021-04-19 2023-12-05 蒙特利尔大学 吡啶并[3,2-d]嘧啶化合物及其用于治疗增殖性疾病的用途

Also Published As

Publication number Publication date
US20120094975A1 (en) 2012-04-19
NZ591493A (en) 2012-07-27
TW201014860A (en) 2010-04-16
CA2736306A1 (en) 2010-03-11
EP2350083B1 (en) 2017-05-17
EP2350083A1 (en) 2011-08-03
AU2009289196A1 (en) 2010-03-11
US8653087B2 (en) 2014-02-18
JP2012502010A (ja) 2012-01-26
MX2011002431A (es) 2011-04-05
ZA201101090B (en) 2012-10-31
KR20110063528A (ko) 2011-06-10
JP5576379B2 (ja) 2014-08-20
WO2010026262A1 (en) 2010-03-11
CL2011000489A1 (es) 2011-07-15
IL211136A0 (en) 2011-04-28
RU2011113402A (ru) 2012-10-20
AR073501A1 (es) 2010-11-10

Similar Documents

Publication Publication Date Title
JP5576379B2 (ja) 細胞増殖阻害剤としてのピリド[5,4−d]ピリミジン
JP5603883B2 (ja) B−Rafキナーゼを阻害するためのピリミドピリミジン誘導体
JP5153773B2 (ja) フェニル置換ヘテロアリール誘導体及び抗癌剤としてのその使用
JP5612573B2 (ja) 新規化学化合物
EP2350052B1 (en) Antiproliferative compounds
US10414769B2 (en) 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors
JP2010531850A (ja) 新規化合物
JP2011528026A6 (ja) 新規化学化合物
US20100210644A1 (en) Chemical compounds
US11213520B2 (en) Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors
US11304929B2 (en) Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors
CN102448943A (zh) 用于治疗特征在于过度或异常细胞增殖的疾病的2,4-二氨基嘧啶
CN102421762A (zh) 用于治疗癌症的取代的嘧啶
US11261184B2 (en) [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110928